Difference between revisions of "Talk:Extracellular Matrix 1"

From CellBiology
Line 1: Line 1:
 +
===The evolution of metazoan extracellular matrix===
 +
 +
http://jcb.rupress.org/content/196/6/671.abstract?sid=733f699f-93a4-408f-8eba-b998957bf3a6
 +
 +
 
===The fibrillar collagen family===
 
===The fibrillar collagen family===
 
Int J Mol Sci. 2010 Jan 28;11(2):407-26.
 
Int J Mol Sci. 2010 Jan 28;11(2):407-26.

Revision as of 07:57, 29 March 2012

The evolution of metazoan extracellular matrix

http://jcb.rupress.org/content/196/6/671.abstract?sid=733f699f-93a4-408f-8eba-b998957bf3a6


The fibrillar collagen family

Int J Mol Sci. 2010 Jan 28;11(2):407-26.

Exposito JY, Valcourt U, Cluzel C, Lethias C.

Institut de Biologie et Chimie des Protéines, CNRS UMR, Université de Lyon, France. jy.exposito@ibcp.fr <jy.exposito@ibcp.fr>

Abstract

Collagens, or more precisely collagen-based extracellular matrices, are often considered as a metazoan hallmark. Among the collagens, fibrillar collagens are present from sponges to humans, and are involved in the formation of the well-known striated fibrils. In this review we discuss the different steps in the evolution of this protein family, from the formation of an ancestral fibrillar collagen gene to the formation of different clades. Genomic data from the choanoflagellate (sister group of Metazoa) Monosiga brevicollis, and from diploblast animals, have suggested that the formation of an ancestral alpha chain occurred before the metazoan radiation. Phylogenetic studies have suggested an early emergence of the three clades that were first described in mammals. Hence the duplication events leading to the formation of the A, B and C clades occurred before the eumetazoan radiation. Another important event has been the two rounds of "whole genome duplication" leading to the amplification of fibrillar collagen gene numbers, and the importance of this diversification in developmental processes. We will also discuss some other aspects of fibrillar collagen evolution such as the development of the molecular mechanisms involved in the formation of procollagen molecules and of striated fibrils.

PMID: 20386646 http://www.ncbi.nlm.nih.gov/pubmed/20386646

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852846

http://www.mdpi.com/1422-0067/11/2/407/


Collagen Type VI-Related Disorders

Lampe AK, Flanigan KM, Bushby KM. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-. 2004 Jun 25 [updated 2007 Apr 06].

Excerpt Disease characteristics. Collagen type VI-related disorders include Bethlem myopathy and Ullrich congenital muscular dystrophy (CMD). Bethlem myopathy is characterized by the combination of proximal muscle weakness and variable contractures, affecting most frequently the long finger flexors, elbows, and ankles. The onset of Bethlem myopathy may be prenatal (characterized by decreased fetal movements), neonatal (hypotonia or torticollis), in early childhood (delayed motor milestones, muscle weakness, and contractures), or in adulthood (proximal weakness and Achilles tendon or long finger flexor contractures). Because of slow but ongoing progression, more than two-thirds of affected individuals over age 50 years rely on supportive means for outdoor mobility. Respiratory involvement is rare and seems to be related to more severe muscle weakness in later life. Ullrich CMD is characterized by congenital weakness and hypotonia, proximal joint contractures, and striking hyperlaxity of distal joints. Some affected children acquire the ability to walk independently; however, progression of the disease often results in later loss of ambulation. Early and severe respiratory involvement may require artificial ventilatory support in the first or second decade of life. Although originally described as separate entities, Bethlem myopathy and Ullrich CMD represent a clinical continuum in which individuals presenting with intermediate phenotypes could be considered to have either "mild Ullrich CMD" or "severe Bethlem myopathy." Diagnosis/testing. Diagnosis depends on typical clinical features, with the serum creatine kinase concentration usually being normal or only mildly elevated and muscle biopsy showing myopathic or dystrophic changes. In Bethlem myopathy, collagen VI immunolabeling of muscle is usually normal or shows subtle alterations only. In Ullrich CMD, collagen VI immunolabeling is absent or markedly reduced from the endomysium and basal lamina, but may be normal around capillaries. Mutations in the genes COL6A1, COL6A2, and COL6A3 are associated with Bethlem myopathy and Ullrich CMD. Molecular genetic testing is available on a clinical basis. Management. Bethlem myopathy/Ullrich CMD: Physiotherapy advice regarding stretching, splinting, and mobility aids; possible orthopedic assessment if surgery for Achilles tendon contractures is to be considered; respiratory surveillance for possible nocturnal hypoventilation. Prophylaxis of chest infections with vaccination and physiotherapy; aggressive treatment of pulmonary infections. In addition for Ullrich CMD: Assessment of nutritional status and growth; management of feeding difficulties. Active surveillance for development of scoliosis; therapy for scoliosis as indicated. Genetic counseling. Bethlem myopathy is inherited in an autosomal dominant manner and Ullrich CMD classically in an autosomal recessive manner although dominant inheritance secondary to de novo mutations can occur. Individuals with Bethlem myopathy are heterozygous for a COL6A1, COL6A2, or COL6A3 mutation and are symptomatic. They may have an affected parent. Parents of individuals with autosomal recessive Ullrich CMD are usually heterozygous for a COL6A1, COL6A2, or COL6A3 mutation, but do not appear to manifest related symptoms. Each child of an individual with Bethlem myopathy has a 50% chance of inheriting the condition; no individuals with Ullrich CMD have been known to reproduce. The risk to the sibs of the proband depends upon the genetic status of the proband's parents. 

For parents of a proband with proven autosomal recessive Ullrich CMD: at conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being neither affected nor a carrier. No laboratories offering direct molecular genetic testing for prenatal diagnosis for Bethlem myopathy or Ullrich CMD are listed in the GeneTests Laboratory Directory. However, prenatal testing may be available for families in which the disease-causing mutation has been identified in an affected family member.

Copyright © 1993-2011, University of Washington, Seattle. All rights reserved.

PMID: 20301676 http://www.ncbi.nlm.nih.gov/pubmed/20301676